Stocks in the FTSE 100 pharma firm, Shire, dropped sharply on Monday morning after it announced a rival had been given permission to make a generic version of its blockbuster treatment for Attention Deficit Hyperactivity Disorder (ADHD), Adderall XR.
Swiss firm Actavis has been given the all clear by the US Food and Drug Administration to manufacture a generic form of Adderall, which analysts at Nomura estimate is worth around 10% of Shire's total earnings per share.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Review: Eden Roc Cap Cana – fun, sun and golf in the CaribbeanTravel Eden Roc Cap Cana in the Dominican Republic offers everything from relaxing by the pool to a world-class golf course
-
Reeves delays cash ISA reform, but savers are not out of the woods yetThe chancellor has reportedly delayed plans to cut the cash ISA limit, which were set to be announced at Mansion House on 15 July, and will take more time to consult with the industry
